Stock AIAI NETRAMARK HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News NetraMark Holdings Inc.

Equities

AIAI

CA64119M1059

Market Closed - Canadian Securities Exchange
Other stock markets
 02:52:39 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.315 CAD 0.00% Intraday chart for NetraMark Holdings Inc. +1.61% -10.00%
Apr. 10 Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations CI
Apr. 04 NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS
AQ
Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations
CI
NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS
AQ
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD
AQ
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board
CI
NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS
AQ
NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE
AQ
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response
CI
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights
MT
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING
AQ
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution
CI
NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024
AQ
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial
CI
NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS
AQ
NetraMark Holdings Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
CI
Netramark Holdings Inc. Announces Presentations of New Data Demonstrating the Application of Its Netraai Clinical Solution to Data Sets of Less Than 400 Patients
CI
NETRAMARK'S AI-BASED TECHNOLOGY IDENTIFIES SIGNIFICANT DRIVERS OF EFFICACY AND PLACEBO RESPONSES AND HAS POTENTIAL TO IMPROVE SUCCESS RATES FOR CLINICAL TRIALS OF PSYCHIATRIC MEDICATIONS
AQ
NetraMark Holdings Inc. to Present New Data Supporting the Potential of Its Proprietary NetraAI Clinical Trial Solution to De-Risk Clinical Trials
CI
NETRAMARK TO PRESENT NEW DATA DEMONSTRATING THE POWER OF ITS AI BASED TECHNOLOGY TO DE-RISK NEUROLOGY CLINICAL TRIALS AT ISCTM ANNUAL MEETING
AQ
NETRAMARK ANNOUNCES LAUNCH OF THE NETRA AI LAB
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AIAI Stock
  4. News NetraMark Holdings Inc.